Member LoginDividend CushionValue Trap
|
Valuentum
Reports
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for
any changes.
Latest
Valuentum Commentary
Jan 19, 2017
The Dreaded Patent Cliff: 3 Pharmaceutical Companies at Risk
Image Source: Global Panorama. Let's have a look at 3 pharmaceutical giants that may encounter some troubles in coming years. Dec 24, 2016
Dividend Increases/Decreases for the Week Ending December 23
Let's take a look at companies raising/lowering their dividends this week. Nov 16, 2016
Pharma, Biotech and How to Consider Investing In It
The Valuentum analyst team digs deep into recent trends in big pharma and biotech from the lofty pricing of drugs to political and competitive pressures to ETF considerations and beyond. ~10 mins. May 17, 2016
Big Pharma 1Q Earnings Roundup, Part II
Image Source: Paw Paw. Let’s take a look at the first quarter performance and some major news for some of the biggest players in the pharmaceuticals sector. Included in this article: ABBV, AGN, BMY, AMGN, MRK, PFE. Feb 22, 2016
Key Treatment Momentum Drives Big Pharma
Let’s take a look at the recent results of some of the biggest names in Big Pharma. Dec 21, 2015
Dividend Increases/Decreases for the Week Ending December 18
Let's take a look at companies raising/lowering their dividends this week. Aug 13, 2015
Big Pharma Earnings Continued…
Amgen, AstraZeneca, Merck, and Pfizer... Dec 22, 2014
Dividend Increases for the Week Ending December 19
Let's take a look at dividend increases for the week ending December 19. Jul 30, 2014
Big Pharma Round Up
Let’s take a look at recent quarterly results from Big Pharma. Jun 22, 2014
Valuentum Economic Castle™ Rating Update
Members should expect the initial Economic Castle™ ratings. Latest News and Media The High Yield Dividend Newsletter, Best Ideas
Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on
this website are for information purposes only and should not be considered a solicitation to buy or sell any
security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s
accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or
omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts
no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a
registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees,
and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.
|
|||||||||||||||||||||
